Alpha 2.0
Login Register
» Authors » Helen Baldomero

Helen Baldomero

Explore the profile of Helen Baldomero including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 72
Citations 1608
Followers 0
Related Specialties
Hematology
General Surgery
General Medicine
Top 10 Co-Authors
Alois Gratwohl
Jakob Passweg
Dietger Niederwieser
John A Snowden
Jakob R Passweg
Urs Schanz
Nicolaus Kroger
Anna Sureda
Mohamad Mohty
Mahmoud Aljurf
Published In
Bone Marrow Transplant
Haematologica
Tissue Eng Part A
Swiss Med Wkly
Biol Blood Marrow Transplant
Affiliations
Soon will be listed here.
Recent Articles
1.
The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT
Passweg J, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al.
Bone Marrow Transplant . 2025 Feb; PMID: 39939433
In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were...
2.
Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT
Passweg J, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, et al.
Bone Marrow Transplant . 2024 Nov; 60(2):227-236. PMID: 39578528
We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received...
3.
Special Report: Summary of the eighth workshop of the worldwide network for blood and marrow transplantation on the status and issues related to hematopoietic stem cell transplantation in near-east countries, held in Pakistan from September 22 to...
Greinix H, Iftikhar R, Chaudhry Q, Ahmed P, Al-Khabori M, Gaziev J, et al.
Hematol Oncol Stem Cell Ther . 2024 Oct; 17(3):190-199. PMID: 39412755
The eighth workshop of the Worldwide Network for Blood and Marrow Transplantation (WBMT) was held in Islamabad, Pakistan, from September 22 to 23, 2022, aiming to foster hematopoietic stem cell...
4.
The role of registries in hematological disorders
Baldomero H, Neumann D, Hamad N, Atsuta Y, Sureda A, Iida M, et al.
Best Pract Res Clin Haematol . 2024 Aug; 37(2):101556. PMID: 39098798
Hematopoietic cell transplantation (HCT) was developed more than 65 years ago to treat malignant blood disorders and irreversible bone marrow failures, with the aim of replacing a diseased hematopoietic system...
5.
Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugs
Heim D, Baldomero H, Medinger M, Masouridi-Levrat S, Schanz U, Nair G, et al.
Swiss Med Wkly . 2024 May; 154:3754. PMID: 38749067
Aim: Until the year 2000, allogeneic haematopoietic cell transplantation (HCT) was the standard treatment for young and fit chronic myeloid leukaemia (CML) patients. CML was the main indication for allogeneic...
6.
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos J, Iida M, et al.
Haematologica . 2024 May; 109(10):3282-3294. PMID: 38721749
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for...
7.
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Passweg J, Baldomero H, Ciceri F, de la Camara R, Glass B, Greco R, et al.
Bone Marrow Transplant . 2024 Mar; 59(6):803-812. PMID: 38438647
In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were...
8.
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021
Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, et al.
Hematol Oncol . 2023 Dec; 42(1):e3241. PMID: 38058031
The Swiss Blood Stem Cell Transplantation and Cellular Therapy Group (SBST) leads a mandatory national registry for all hematopoietic stem cell transplants (HCT) and cellular therapies. After 25 years, information...
9.
Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT
Styczynski J, Tridello G, Koster L, Knelange N, Wendel L, van Biezen A, et al.
Bone Marrow Transplant . 2023 May; 58(8):881-892. PMID: 37149673
We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence...
10.
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT...
Saccardi R, Putter H, Eikema D, Busto M, McGrath E, Middelkoop B, et al.
Bone Marrow Transplant . 2023 Mar; 58(6):659-666. PMID: 36894635
From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT...